Codexis Appoints Vice President of Sales and Marketing
News Jun 06, 2013
Codexis, Inc. has announced the appointment of Scott Watson as Vice President of Sales and Marketing, effective May 2013.
Mr. Watson has more than 25 years of experience in sales, marketing and business development, including in the pharmaceutical and fine chemicals markets.
“Scott brings a strong track record of success to Codexis, along with a wealth of knowledge and connections from his various roles in the pharmaceutical and fine chemical industries,” said John Nicols, President and CEO of Codexis.
Nicols continued, “We continue to expand our pharmaceutical business through new collaborations with strategic partners, and this hire will allow us to capitalize on the many opportunities within both the pharmaceutical industry and other complex chemistry markets where our tailored enzymes can provide significant benefits for our customers.”
“Codexis is the world leader in developing biocatalysts for the pharmaceutical industry and I am very excited to be joining the team at this time,” said Scott Watson.
Watson continued, “The opportunities in the pharmaceutical market continue to grow, and I look forward to helping Codexis further expand its presence, in pharmaceutical and other complex chemistry markets, during the coming years.”
Before joining Codexis, Mr. Watson served most recently as the Executive Director of Sales and Marketing at AMPAC Fine Chemicals, a leading manufacturer of custom small molecule active pharmaceutical ingredients.
From 2008 to 2009, Mr. Watson served as Vice President of Sales and Marketing for Girindus, a diverse service company to the pharmaceutical industry, where he was responsible for realigning the company’s sales strategy.
Prior to Girindus, Mr. Watson held sales positions of growing responsibility with various companies, including Aptuit, DSM and Eastman Chemical Company.
Mr. Watson is a former officer in the U.S. Navy and holds a B.S. in Chemistry from the U.S. Naval Academy and an M.B.A. in Finance and Marketing from George Mason University.
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
A New Tactic in the Fight Against Drug-Resistant InfectionsNews
$1 million research grant could lead to life-saving antibiotics.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018